LCM
CPRX

Legato Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Legato Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$616K Sell
24,889
-33,857
-58% -$807K 0.06% 481
2025
Q4 		$1.37M Buy
58,746
+10,488
+22% +$234K 0.12% 275
2025
Q3 		$951K Buy
48,258
+18,147
+60% +$373K 0.1% 304
2025
Q2 		$653K Sell
30,111
-23,541
-44% -$556K 0.08% 389
2025
Q1 		$1.3M Buy
+53,652
New +$1.21M 0.18% 187

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Legato Capital Management's CPRX Position: Q1 2026 in Review

Legato Capital Management reduced its Catalyst Pharmaceutical (CPRX) stake by 58% in Q1 2026, selling an estimated $807K and leaving 24,889 shares worth $616K. The position accounts for 0.06% of the portfolio, ranked #481.

Legato Capital Management first reported a position in CPRX in Q1 2025 and has held it in 5 quarters since. The position peaked at $1.37M in Q4 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Legato Capital Management held 24,889 shares of Catalyst Pharmaceutical worth $616K as of Q1 2026.
  • Legato Capital Management sold 33,857 Catalyst Pharmaceutical shares in Q1 2026, an estimated $807K.
  • Catalyst Pharmaceutical made up 0.06% of Legato Capital Management's portfolio in Q1 2026, its #481 holding.
  • Legato Capital Management first reported a position in Catalyst Pharmaceutical in Q1 2025 and has held it in 5 quarters since.
  • Legato Capital Management's Catalyst Pharmaceutical position peaked at $1.37M in Q4 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Legato Capital Management's 13F filing for Q1 2026, filed 14 May 2026.